This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Threshold's Pancreatic Cancer Drug May be Obsolete Before Launch

Bulls contend that FOLFIRINOX is too toxic for most patients to tolerate. I'm not so sure that's true, and physician opinions vary. Importantly, despite the increased toxicity, FOLFIRINOX-treated patients in the NEJM study had a significantly longer "time to deterioration," as measured by quality of life scores, than did those in the gemcitabine arm. Meanwhile, Threshold's investigators have noted that low dose TH-302 recipients demonstrate improved dose intensity -- a measure of tolerability -- than those treated with higher doses. Those factors indicate that TH-302 isn't devoid of meaningful adverse effects, and suggest that FOLFIRINOX may be less toxic than feared.

The NEJM study results also appear to be reproducible. A study published earlier this month (Peddi et al. J Pancreas 2012 Sep 10; 13(5):497-501) by investigators from the Mayo Clinic, Washington University, and University of Wisconsin demonstrates even better outcomes for PFS (7.5 months) and overall survival (13.5 months) with FOLFIRINOX. Admittedly, this is a single-arm trial in relatively very healthy individuals, but the investigators conclusion is noteworthy: " more effective than any other regimen in patients with pancreatic cancer and its toxicities did not preclude its use in the patients studied in this review."

Threshold's pivotal phase III trial, which is still being planned, will compare TH-302 against FOLFIRINOX and increase the risk of failure, or against gemcitabine and risk irrelevance. I'm assuming the latter. In that case, TH-302 may prove modestly effective compared to gemcitabine, but it won't reach the market for at least three years.

Further, I'm not sure how Threshold and partner Merck KGaA intend to differentiate TH-302 and justify branded pricing, especially given that inexpensive generic alternatives like FOLFIRINOX seem to have superior efficacy. Lastly, several competitors will report pivotal trial data for novel agents in pancreatic cancer over the next six months, most notably Celgene's (CELG - Get Report) Abraxane and Clovis Oncology's (CLVS) CO-101. Should any of those drugs show a meaningful benefit, the bull case on Threshold will be even harder to make.

For more on Threshold, read columnist Adam Feuerstein's view of the TH-302 pancreatic cancer data.

Sadeghi has no position in any stocks mentioned in this column.

Follow Nathan Sadeghi-Nejad on Twitter.
Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza's Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
LLY $73.72 -0.81%
THLD $0.29 1.00%
CELG $98.92 1.10%
CLVS $18.99 -4.40%
FB $100.59 -3.30%


Chart of I:DJI
DOW 15,905.63 -299.34 -1.85%
S&P 500 1,843.38 -36.67 -1.95%
NASDAQ 4,260.0340 -103.11 -2.36%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs